Effect of anti-TNF treatment on body composition and serum adiponectin levels of women with rheumatoid arthritis

Clinical Rheumatology

Volumn 27, Issue 6, 2008, Pages 795-797

  Serelis, John ^a   Kontogianni, Meropi D ^b   Katsiougiannis, Stergios ^b   Bletsa, Maria ^b   Tektonidou, Maria G ^a   Skopouli, Fotini N ^a,b  

^a Athens Euroclinic ^*  (Greece)

^b HAROKOPIO UNIVERSITY   (Greece)

Author keywords

Adiponectin; Anti TNF treatment; Bone mineral density; Lean body mass; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ADIPONECTIN; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; INFLIXIMAB; METHOTREXATE; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VITAMIN D;

ADULT; AGED; ARTICLE; BODY COMPOSITION; BONE DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; LOW DRUG DOSE; LUMBAR SPINE; OSTEOPOROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RHEUMATOID ARTHRITIS; TREATMENT DURATION;

ADIPONECTIN; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BODY COMPOSITION; BONE DENSITY; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; METHOTREXATE; MIDDLE AGED; STEROIDS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 43249112944     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-008-0855-7     Document Type: Article

References (18)

1. Westhovens R, Nijs J, Taelman V et al (1997) Body composition in rheumatoid srthritis. Br J Rheumatol 36:448-448 Apr
2. Munro R, Capell H (1997) Prevalence of low body mass in rheumatoid arthritis: Association with the acute phase response. Ann Rheum Dis 56:326-329
3. Roubenoff R, Roubenoff RA, Cannon JG et al (1994) Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest 93:2379-2386
4. Scherer PE, Williams S, Fogliano M et al (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270:26746-26749
5. Yamauchi T, Kamon J, Minokoshi Y et al (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1295
6. Kontogianni MD, Dafni UG, Routsias JG et al (2004) Blood leptin and adiponectin as possible mediators of the relation between fat mass and BMD in perimenopausal women. J Bone Miner Res 19:546-551
7. Arita Y, Kihara S, Ouchi N et al (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83
8. Hector J, Schwarzloh B, Goehring J et al (2007) TNF-alpha alters visfatin and adiponectin levels in human fat. Horm Metab Res 39:250-255
9. Shioji K, Moriwaki S, Takeuchi Y et al (2007) Relationship of serum adiponectin to level of adverse cardiovascular events in patients who undergo percutaneous coronary intervention. Circ J 71:675-680
10. Stefan N, Ehling A, Neumann E et al (2003) Adipocytokines in synovial fluid. JAMA 290:1709-1710
11. Ehling A, Schäffler A, Herfarth H et al (2006) The potential of adiponectin in driving arthritis. J Immunol 176:4468-4478
12. van Gestel AM, Haagsma CJ, van Riel PL (1998) Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 41:1845-1850
13. Vis M, Havaardsholm EA, Haugeberg G et al (2006) Evaluation of bone mineral density, bone metabolism, osteoprotegerin and rankl serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 65:1495-1499
14. Marcora SM, Chester KR, Mittal G et al (2006) Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr 84:1463-1472
15. Harle P, Sarzi-Puttini P, Cutolo M et al (2006) No change of serum levels of leptin and adiponectin during anti-tumor necrosis factor antibody treatment with adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis 65:970-971
16. Komai N, Morita Y, Sakuta T et al (2007) Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis. Mod Rheumatol 17:385-390
17. Otero M, Lago R, Gomez R et al (2006) Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 65:1198-1201
18. Senolt L, Pavelka K, Housa D et al (2007) Increased adiponectin is negatively linked to the local inflammatory process in patients with rheumatoid arthritis. Cytokine 38:151-156